PDS Biotechnology (PDSB) to Release Earnings on Wednesday

PDS Biotechnology (NASDAQ:PDSB) is scheduled to post its quarterly earnings results before the market opens on Wednesday, May 15th. Analysts expect PDS Biotechnology to post earnings of ($0.37) per share for the quarter.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings results on Wednesday, March 27th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.05. On average, analysts expect PDS Biotechnology to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PDS Biotechnology Trading Down 3.4 %

Shares of PDS Biotechnology stock opened at $3.65 on Wednesday. PDS Biotechnology has a 1-year low of $2.59 and a 1-year high of $10.27. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.33 and a quick ratio of 4.33. The stock has a market cap of $133.88 million, a P/E ratio of -2.74 and a beta of 1.75. The stock’s 50 day simple moving average is $4.13 and its 200-day simple moving average is $4.79.

Wall Street Analyst Weigh In

PDSB has been the subject of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of PDS Biotechnology in a research note on Wednesday, March 27th. Cantor Fitzgerald reissued an “overweight” rating on shares of PDS Biotechnology in a research note on Friday, January 12th. StockNews.com cut PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, March 16th. Finally, B. Riley reissued a “buy” rating and set a $11.00 target price (down previously from $14.00) on shares of PDS Biotechnology in a research note on Thursday, March 28th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.33.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.